CN114652816A - 含有hc-ha/ptx3复合物的组合物及其使用方法 - Google Patents

含有hc-ha/ptx3复合物的组合物及其使用方法 Download PDF

Info

Publication number
CN114652816A
CN114652816A CN202210284199.XA CN202210284199A CN114652816A CN 114652816 A CN114652816 A CN 114652816A CN 202210284199 A CN202210284199 A CN 202210284199A CN 114652816 A CN114652816 A CN 114652816A
Authority
CN
China
Prior art keywords
ptx3
rchc
nhc
complex
tsg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210284199.XA
Other languages
English (en)
Chinese (zh)
Inventor
谢弗·曾
贺华
肖恩·泰伊
素珍·张
英腾·朱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TissueTech Inc
Original Assignee
TissueTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TissueTech Inc filed Critical TissueTech Inc
Publication of CN114652816A publication Critical patent/CN114652816A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
CN202210284199.XA 2012-07-11 2013-07-10 含有hc-ha/ptx3复合物的组合物及其使用方法 Pending CN114652816A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261670571P 2012-07-11 2012-07-11
US61/670,571 2012-07-11
PCT/US2013/049983 WO2014011813A1 (en) 2012-07-11 2013-07-10 Compositions containing hc-ha/ptx3 complexes and methods of use thereof
CN201380047367.2A CN104619352B (zh) 2012-07-11 2013-07-10 含有hc-ha/ptx3复合物的组合物及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380047367.2A Division CN104619352B (zh) 2012-07-11 2013-07-10 含有hc-ha/ptx3复合物的组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN114652816A true CN114652816A (zh) 2022-06-24

Family

ID=48916179

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210284199.XA Pending CN114652816A (zh) 2012-07-11 2013-07-10 含有hc-ha/ptx3复合物的组合物及其使用方法
CN201380047367.2A Active CN104619352B (zh) 2012-07-11 2013-07-10 含有hc-ha/ptx3复合物的组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380047367.2A Active CN104619352B (zh) 2012-07-11 2013-07-10 含有hc-ha/ptx3复合物的组合物及其使用方法

Country Status (9)

Country Link
US (5) US10040821B2 (ja)
EP (2) EP2872181B1 (ja)
JP (3) JP2015528001A (ja)
KR (1) KR102236805B1 (ja)
CN (2) CN114652816A (ja)
CA (1) CA2878163A1 (ja)
ES (1) ES2846789T3 (ja)
HK (1) HK1210425A1 (ja)
WO (1) WO2014011813A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115843780A (zh) * 2022-11-18 2023-03-28 广州瑞泰生物科技有限公司 生物膜保存液及其制备方法和应用

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP1933852B1 (en) 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
WO2010124296A2 (en) 2009-04-24 2010-10-28 Tissuetech, Inc. Compositions containing hc•ha complex and methods of use thereof
US10040821B2 (en) 2012-07-11 2018-08-07 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US10537648B2 (en) 2014-06-25 2020-01-21 Novartis Ag Compositions and methods for visualization of the vitreous
WO2016018761A1 (en) * 2014-07-28 2016-02-04 The Texas A&M University System Mesenchymal stem cells expressing biomarkers that predict the effectiveness of the mesenchymal stem cells for treating diseases and disorders
DE102015210890A1 (de) 2014-10-02 2016-04-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Trockenprodukt aus Obst und/oder Gemüse sowie Verfahren zur Herstellung
CN107847526A (zh) 2015-05-20 2018-03-27 组织技术公司 用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
CN104988119A (zh) * 2015-07-08 2015-10-21 深圳爱生再生医学科技有限公司 沃顿胶消化液
CN104988118A (zh) * 2015-07-08 2015-10-21 深圳爱生再生医学科技有限公司 脐带间充质干细胞的制备方法
CN105353113B (zh) * 2015-11-05 2017-09-08 中国科学院武汉病毒研究所 洛拉曲塞或其药学上可接受的盐在制备治疗或预防疱疹病毒感染药物中的应用
AU2017231832B2 (en) 2016-03-11 2021-11-11 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating crystal arthropathy disorders
JP6967260B2 (ja) * 2016-03-28 2021-11-17 学校法人慶應義塾 移植片対宿主病の治療剤又は予防剤、ファイブロサイト浸潤抑制剤、及び涙液減少と杯細胞の減少の抑制剤
CN106950366B (zh) * 2017-02-15 2019-03-22 中国医学科学院北京协和医院 一种acpa阴性的ra诊断标志物及其应用
WO2019056991A1 (zh) * 2017-09-19 2019-03-28 臻崴生物科技有限公司 单克隆抗体或其抗原结合片段及其用途
US10251917B1 (en) * 2017-09-19 2019-04-09 Gary M. Petrucci Methods and materials for treating tumors
US11285177B2 (en) 2018-01-03 2022-03-29 Globus Medical, Inc. Allografts containing viable cells and methods thereof
EP4371535A3 (en) 2018-02-22 2024-08-14 Alcon Inc. Ocular implant
CN114470001A (zh) * 2018-04-18 2022-05-13 浙江大学 人羊膜上皮细胞在自身免疫性疾病中的治疗用途
CN112770742A (zh) 2018-07-27 2021-05-07 阿佩塔生物科学有限公司 用于治疗蠕形螨引起的眼部和面部疾病的多杀菌素制剂
WO2020061688A1 (en) * 2018-09-24 2020-04-02 The University Of British Columbia Modulation of granzyme k activity in the treatment of skin conditions
CN110946988B (zh) * 2018-09-26 2022-11-29 臻崴生物科技有限公司 短肽用于制备抑制或减缓虾过敏反应的药物组合物的用途
CN112912065A (zh) * 2018-10-24 2021-06-04 普罗瑟拉生物公司 间α抑制剂蛋白及其使用方法
CA3117723A1 (en) * 2018-11-07 2020-05-14 Tissuetech, Inc. Methods of cellular reprogramming
JP2022529022A (ja) * 2019-04-16 2022-06-16 ライフネット ヘルス 出産組織由来の生成物並びにその調製及び使用
JP2022535089A (ja) * 2019-06-06 2022-08-04 アロア・バイオサージェリー・リミテッド 生物活性剤及びそれに関連した方法
CA3144419A1 (en) 2019-06-20 2020-12-24 Tissuetech, Inc. Methods of promoting vasculogenesis
KR102166453B1 (ko) * 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
AU2021219772A1 (en) * 2020-02-12 2022-09-01 Biotissue Holdings Inc. Methods of killing or inhibiting the growth of cancer cells
CN112924679A (zh) * 2021-01-29 2021-06-08 沈阳金域医学检验所有限公司 Ptx-3在医学检测中的新应用
KR102678583B1 (ko) * 2021-05-31 2024-06-27 중앙대학교 산학협력단 Hapln1을 포함하는 혈관질환 예방 또는 치료용 조성물
WO2023128674A1 (ko) * 2021-12-30 2023-07-06 주식회사 하플사이언스 Hapln1을 포함하는 안구건조증의 예방 또는 치료용 조성물
WO2023211823A1 (en) * 2022-04-25 2023-11-02 Biotissue Holdings Inc. Compositions and methods relating to pooled fetal support tissue
CN114870031B (zh) * 2022-05-20 2023-07-07 四川大学 一种cd44靶向的紫杉烷类纳米晶体及其制备方法与应用
CN114939190B (zh) * 2022-06-14 2024-01-12 健诺维(成都)生物科技有限公司 一种用于青光眼治疗的引流管材料及其制备方法
CN115845141B (zh) * 2023-03-02 2023-05-16 健诺维(成都)生物科技有限公司 一种干态羊膜的制备方法及应用
CN117159588B (zh) * 2023-11-01 2024-02-13 北京国卫生物科技有限公司 脐带间充质干细胞治疗骨关节炎的细胞治疗方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316602A (zh) * 2005-09-27 2008-12-03 组织技术公司 羊膜制品和纯化的组合物及其使用方法
US20120083445A1 (en) * 2009-04-24 2012-04-05 Tissuetech, Inc. Compositions Containing HC-HA Complex and Methods of Use Thereof
CN104619352A (zh) * 2012-07-11 2015-05-13 组织技术公司 含有hc-ha/ptx3复合物的组合物及其使用方法

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
SE8200751L (sv) 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5093487A (en) 1986-01-06 1992-03-03 Mobay Corporation Low viscosity high molecular weight filter sterilizable hyaluronic acid
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US5037677A (en) 1984-08-23 1991-08-06 Gregory Halpern Method of interlaminar grafting of coatings
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
JPH0778017B2 (ja) 1985-12-28 1995-08-23 住友製薬株式会社 パルス的かつ持続放出性製剤
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
WO1991001720A1 (en) 1989-08-07 1991-02-21 Herman Wade Schlameus Composition and method of promoting hard tissue healing
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5356433A (en) 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
KR100274734B1 (ko) 1991-11-22 2000-12-15 제이코버스 코넬리스 레이서 리제드로네이트 지연-방출성 조성물
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5437287A (en) 1992-08-17 1995-08-01 Carbomedics, Inc. Sterilization of tissue implants using iodine
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5336518A (en) 1992-12-11 1994-08-09 Cordis Corporation Treatment of metallic surfaces using radiofrequency plasma deposition and chemical attachment of bioactive agents
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6203755B1 (en) 1994-03-04 2001-03-20 St. Jude Medical, Inc. Electron beam sterilization of biological tissues
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
CA2220451A1 (en) 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methods and compositions for improving digestion and absorption in the small intestine
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5932545A (en) 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US20030068815A1 (en) 1999-02-11 2003-04-10 Stone Kevin R. Sterilized xenograft tissue
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6521179B1 (en) 1999-08-11 2003-02-18 Biomedical Design, Inc. Sterilization
US6573249B2 (en) 2000-02-15 2003-06-03 Alphamed Pharmaceutical Corp. Topical wound therapeutic compositions
KR20010098716A (ko) 2000-04-19 2001-11-08 김재찬 안구표면질환 치료용 양막 추출물
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
ES2607802T3 (es) 2001-08-14 2017-04-04 Tel Aviv University Future Technology Development L.P. Partículas lipidadas de glicosaminoglicano y su uso en el suministro de fármacos y genes para diagnóstico y terapia
US20030180181A1 (en) 2002-02-01 2003-09-25 Teri Greib Methods for sterilizing tissue
TWI290055B (en) 2002-03-14 2007-11-21 Tissuetech Inc Amniotic membrane covering for a tissue surface and devices facilitating fastening of membranes
ES2398239T3 (es) 2003-11-10 2013-03-14 The Scripps Research Institute Composiciones y procedimientos para inducir la desdiferenciación celular
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
GB0514567D0 (en) 2005-07-15 2005-08-24 Univ Nottingham Surgical membrane
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US20080102135A1 (en) 2006-10-28 2008-05-01 Franck Jean Ollivier Use of equine amniotic membrane in ophthalmic surgeries in veterinary medicine
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009111159A2 (en) 2008-03-03 2009-09-11 New York University Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same
US20100000375A1 (en) 2008-07-07 2010-01-07 Steinbock Robert C Tamper resistant jackbolts for a tensioner
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
CA2815689C (en) 2010-11-11 2016-11-22 Abbvie Biotechnology Ltd. Improved high concentration anti-tnf.alpha. antibody liquid formulations
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
IL247063B (en) 2013-10-07 2022-09-01 Mor Research Applic Ltd Treatments for Pi. Wee. R. (pvr)
US20160326487A1 (en) 2014-01-08 2016-11-10 Samsung Life Public Welfare Foundation Stem Cells Derived from Pure Chorionic Trophoblast Layer and Cell Therapy Comprising Same
RU2714236C2 (ru) 2014-08-14 2020-02-13 Авита Интернэшнл Лтд. Композиции стволовых клеток и способы получения стволовых клеток для применения в терапии
CN107847526A (zh) 2015-05-20 2018-03-27 组织技术公司 用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
WO2017096615A1 (zh) 2015-12-11 2017-06-15 郭镭 一种从脐带华通氏胶组织中分离提取hUC-MSC的方法
WO2017096617A1 (zh) 2015-12-11 2017-06-15 郭镭 一种用于分步培养hUC-MSC的试剂盒及采用所述试剂盒获得的hUC-MSC
WO2017096616A1 (zh) 2015-12-11 2017-06-15 郭镭 一种无血清培养基及其制备方法和用途
WO2017136557A1 (en) 2016-02-05 2017-08-10 Petrucci Gary M Methods and materials for treating nerve injuries and neurological disorders
US20170354692A1 (en) 2016-06-13 2017-12-14 MAM Holdings of West Florida, L.L.C. Amniotic fluid formulation for treatment of lung disorders
IL264536B2 (en) 2016-08-24 2023-09-01 Arthrex Inc Use of tissue for injury repair
CA3031978A1 (en) 2016-10-05 2018-04-12 Cellresearch Corporation Pte. Ltd. A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium
EP3534920A4 (en) 2016-11-07 2020-07-15 Ise Professional Testing & Consulting Services, Inc. DECELLULARIZED BIOMATERIAL FROM MAMMAL TISSUE
US20180163177A1 (en) 2016-12-11 2018-06-14 Healthbanks Biotech Co. Ltd. Serum-free culture medium and method for expanding hematopoietic stem cells
US10993904B2 (en) 2016-12-23 2021-05-04 Inscobee Inc. Transplantation implant for promoting hair growth
US20180177989A1 (en) 2016-12-28 2018-06-28 Regen Medical Inc. Vaginal rejuvenation methods and devices
TWI746772B (zh) 2017-01-18 2021-11-21 國立陽明大學 臍帶間質幹細胞用於治療肺部纖維化之用途
US20180264049A1 (en) 2017-03-20 2018-09-20 Batu Biologics, Inc. Immunotherapy of Aberrant Ocular Angiogenesis by Placental Vaccination
US20180271914A1 (en) 2017-03-21 2018-09-27 Noveome Biotherapeutics, Inc. Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury
US20180311408A1 (en) 2017-05-01 2018-11-01 Trojan Medical Solutions, LLC Amnion based conduit tissue
WO2018220489A2 (en) 2017-06-02 2018-12-06 Janssen Biotech, Inc. Methods of obtaining cells from human postpartum umbilical cord arterial tissue
WO2018220490A1 (en) 2017-06-02 2018-12-06 Janssen Biotech, Inc. Method of modulating müller glia cells
US20190134100A1 (en) 2017-11-03 2019-05-09 Janssen Biotech, Inc. Method of inhibiting angiogenesis
WO2019099503A1 (en) 2017-11-14 2019-05-23 Cook Biotech Incorporated Preserved tissue products and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316602A (zh) * 2005-09-27 2008-12-03 组织技术公司 羊膜制品和纯化的组合物及其使用方法
US20120083445A1 (en) * 2009-04-24 2012-04-05 Tissuetech, Inc. Compositions Containing HC-HA Complex and Methods of Use Thereof
CN104619352A (zh) * 2012-07-11 2015-05-13 组织技术公司 含有hc-ha/ptx3复合物的组合物及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUA HE ET AL.: "Biochemical Characterization and Function of Complexes Formed by Hyaluronan and the Heavy Chains of Inter-α-inhibitor (HC•HA) Purified from Extracts of Human Amniotic Membrane", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 30, 24 July 2007 (2007-07-24), pages 1 - 20 *
SHUNSUKE R. SAKURAI ET AL.: "Characterization of the role of PTX3 in enhancing the anti-angiogenic action of HC-HA purified from the chorion", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 52, 30 April 2011 (2011-04-30), pages 4881 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115843780A (zh) * 2022-11-18 2023-03-28 广州瑞泰生物科技有限公司 生物膜保存液及其制备方法和应用

Also Published As

Publication number Publication date
US20150166624A1 (en) 2015-06-18
EP2872181B1 (en) 2020-11-18
US20160376305A1 (en) 2016-12-29
HK1210425A1 (en) 2016-04-22
US20190169231A1 (en) 2019-06-06
EP2872181A1 (en) 2015-05-20
JP2017014234A (ja) 2017-01-19
US10253065B2 (en) 2019-04-09
KR102236805B1 (ko) 2021-04-05
CN104619352A (zh) 2015-05-13
JP6472142B2 (ja) 2019-02-20
US20230279048A1 (en) 2023-09-07
CA2878163A1 (en) 2014-01-16
EP3838293A1 (en) 2021-06-23
US10717763B2 (en) 2020-07-21
WO2014011813A1 (en) 2014-01-16
KR20150053753A (ko) 2015-05-18
US20200308219A1 (en) 2020-10-01
US11518782B2 (en) 2022-12-06
JP2015528001A (ja) 2015-09-24
US10040821B2 (en) 2018-08-07
JP2019178144A (ja) 2019-10-17
CN104619352B (zh) 2022-02-18
ES2846789T3 (es) 2021-07-29

Similar Documents

Publication Publication Date Title
US10717763B2 (en) Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US20120083445A1 (en) Compositions Containing HC-HA Complex and Methods of Use Thereof
JP2009073845A (ja) ミエリン会合糖タンパク質（ｍａｇ）およびそのインヒビターを用いた組成物および方法
KR20180043317A (ko) 조직 형성 유도용 화합물 및 그것의 용도
US20190225651A1 (en) Compounds for inducing tissue formation and uses thereof
KR20180052682A (ko) 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
JP2022046727A (ja) 組織形成誘導用化合物及びその使用
WO2022006076A1 (en) Ocular treatment compositions and methods
US20230083005A1 (en) Methods of killing or inhibiting the growth of cancer cells
US9662417B2 (en) Medical device
JPH02215730A (ja) 細胞増殖抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Florida, USA

Applicant after: Biotissue Holding Co.

Address before: Florida, USA

Applicant before: TISSUETECH, Inc.

Country or region before: U.S.A.